Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Jessica Mitacek

Hims & Hers’ Revenue Beat Came With a Profitability Problem

After recently receiving the unwelcome news about Hims & Hers Health (NYSE: HIMS) being sued by the U.S. Federal Trade Commission (FTC), California, and Utah, investors were dealt another blow on Monday, Aug. 10.

The telehealth platform, which provides direct-to-consumer (D2C) personal care products and virtual medical services, reported Q2 results, which included its second consecutive earnings miss and its fourth in the past five quarters.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.